[go: up one dir, main page]

Hatano et al., 1989 - Google Patents

D2-dopamine receptor specific brain uptake of carbon-11-labeled YM-09151-2

Hatano et al., 1989

View PDF @Free from Publisher
Document ID
11966198008950498544
Author
Hatano K
Ishiwata K
Kawashima K
Hatazawa J
Itoh M
Ido T
Publication year
Publication venue
Journal of nuclear medicine

External Links

Snippet

D2-Dopamine Receptor Specific Brain Uptake Page 1 he measurement ofneurotransmitter specific recep tors has advanced rapidly with the in vitro steady-state method using membrane preparations of nerve cells, and this methodology has opened new insights in …
Continue reading at jnm.snmjournals.org (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids

Similar Documents

Publication Publication Date Title
Hatano et al. D2-dopamine receptor specific brain uptake of carbon-11-labeled YM-09151-2
US5219548A (en) High affinity halogenated-tamoxifen derivatives and uses thereof
Kiesewetter et al. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats
Kung et al. In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans
US7408079B2 (en) Imaging agents and methods of imaging NAALADase or PSMA
US6096874A (en) High affinity tamoxifen derivatives
Sanad et al. Radioiodination and bioevaluation of rolipram as a tracer for brain imaging: in silico study, molecular modeling and gamma scintigraphy
Navarro et al. Prosthetic groups for radioiodination and astatination of peptides and proteins: A comparative study of five potential bioorthogonal labeling strategies
Choi et al. Development of a Tc-99m labeled sigma-2 receptor-specific ligand as a potential breast tumor imaging agent
Halldin et al. (S)-and (R)-[11C] nicotine and the metabolite (RS)-[11C] cotinine. Preparation, metabolite studies and in vivo distribution in the human brain using PET
Sanad et al. Radiocomplexation and bioevaluation of 99mTc nitrido-piracetam as a model for brain imaging
AU664161B2 (en) High affinity tamoxifen derivatives and uses thereof
US5320825A (en) Serotonin reuptake inhibitors for S.P.E.C.T. imaging
Vaidyanathan et al. (4-[18F] Fluoro-3-iodobenzyl) guanidine, a Potential MIBG Analog for Positron Emission Tomography
Eskola et al. Tracer level electrophilic synthesis and pharmacokinetics of the hypoxia tracer [18F] EF5
Soloviev et al. Asymmetric synthesis and preliminary evaluation of (R)-and (S)-[11C] bisoprolol, a putative β1-selective adrenoceptor radioligand
US5886190A (en) Rapid synthesis and use of 18F-fluoromisonidazole and analogs
Fowler et al. Synthesis and preliminary evaluation in animals of carrier-free 11C-1-dopamine hydrochloride: X
JP5085824B2 (en) Production of compounds useful for hypoxia detection
Sanad et al. Radiocomplexation, Chromatographic Separation and Bioevaluation of [99mTc] Dithiocarbamate of Procainamide as Selective Labeled Compound for Myocardial Perfusion Imaging
Moresco et al. Systemic and cerebral kinetics of 16α [18F] fluoro-17β-estradiol: a ligand for the in vivo assessment of estrogen receptor binding parameters
Zhao et al. VMAT2 imaging agent, D6-[18F] FP-(+)-DTBZ: improved radiosynthesis, purification by solid-phase extraction and characterization
Amin et al. Radioiodination and biological evaluation of valsartan as a tracer for cardiovascular disorder detection
WO2022193038A1 (en) [18f]alf labeled psma targeting molecular probe and preparation method therefor
EP2850044B1 (en) Use of fluorinated derivatives of 4-aminopyridine in therapeutics and medical imaging